Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Boooom Booom Monday.....! would be nice to be back at 80p + again.
https://twitter.com/OmegaDiagnostic/status/1355972292656984068
To-do list:
? Launch Mologic ELISA antibody test service
? Massively scale up Alva production facility
? Ensure Mologic Tech Transfer is on track
? Finish ramping up capacity to 2 million tests a week
? Buy office blinds .....
wow .. 81.00 +25.00 +44.64%
Volume: 4,699,678
https://twitter.com/genedriveplc
WOW ... moving fast now - 75.33 +19.33 +34.52%
Volume: 4,179,574
Yes, moving very fast now.
73.15 +17.15 +30.63%
Just look at the market cap £40M compared to others. £5+ is correct MC for GDR.
President Biden announcement yesterday is a game-changer for GDR
President Joe Biden seeks to reset the nation’s inconsistent coronavirus testing efforts with a $50 billion plan and more federal oversight.
Biden’s plan calls for a newly created Pandemic Testing Board to coordinate a “clear, unified approach” to testing for COVID-19, a marked difference from the Trump administration’s policy of states establishing their own plans with federal support.
https://eu.usatoday.com/story/news/health/2021/01/24/bidens-covid-testing-push-calls-more-supplies-and-rapid-tests/4215619001/
COVID stocks soar as UK targets 2m British made rapid tests per day26 Jan 2021 06:34
COVID stocks soar as UK targets 2m British made rapid tests per day
I did my research on Avacta (AVCT), Novacyte (NCYT), Omega Diagnostics (ODX), genedrive (GDR).
1 - Genedrive - 26.54 - 1.06M - the Best opportunity - No orders - waiting for approval - still low - multibagger
2 - Omega - 212.26 - 8.51M I already have a position. - No orders - waiting for approval
3 Avacta - 376.45 - 3.20M - Price Too high & MC too high - No orders - waiting for approval
4 Novacyt - 794.78 - TBC - Too high for me
Https://www.pharmiweb.com/press-release/2021-01-21/covid-19-testing-sector-demand-set-to-continue-amid-vaccine-rollout
71.99 +15.99 +28.55%
Crazy Volume: 2,977,577
I'm not selling until 5+. I remember what happened to NCYT
Massive contracts to follow soon. Remember below.
President Joe Biden seeks to reset the nation’s inconsistent coronavirus testing efforts with a $50 billion plan and more federal oversight.
Look at what happen to NCYT 14p to £12+
It is GDR turn now.
WOW .... 75p now.
Do not miss your chance here.
Look at the charts and see it is going back to £3+
President Biden announcement yesterday is a game-changer for GDR
President Joe Biden seeks to reset the nation’s inconsistent coronavirus testing efforts with a $50 billion plan and more federal oversight.
Biden’s plan calls for a newly created Pandemic Testing Board to coordinate a “clear, unified approach” to testing for COVID-19, a marked difference from the Trump administration’s policy of states establishing their own plans with federal support.
https://eu.usatoday.com/story/news/health/2021/01/24/bidens-covid-testing-push-calls-more-supplies-and-rapid-tests/4215619001/
COVID stocks soar as UK targets 2m British made rapid tests per day26 Jan 2021 06:34
COVID stocks soar as UK targets 2m British made rapid tests per day
I did my research on Avacta (AVCT), Novacyte (NCYT), Omega Diagnostics (ODX), genedrive (GDR).
1 - Genedrive - 26.54 - 1.06M - the Best opportunity - No orders - waiting for approval - still low - multibagger
2 - Omega - 212.26 - 8.51M I already have a position. - No orders - waiting for approval
3 Avacta - 376.45 - 3.20M - Price Too high & MC too high - No orders - waiting for approval
4 Novacyt - 794.78 - TBC - Too high for me
Https://www.pharmiweb.com/press-release/2021-01-21/covid-19-testing-sector-demand-set-to-continue-amid-vaccine-rollout
73p now ..wow
9 o'clock push coming in now.
Latecomers to the party
Going back up quickly at 70p.
Read the RNS - we are up for a reason.
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter") for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive's high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory viral samples. The agreement is the result of the collaboration agreement announced in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation in conjunction with its RNAdvance Viral XP extraction kit.
The Genedrive® 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument. The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent based test formulation. Full automation of the overall PCR workflow can allow laboratories to run large numbers of tests over extended working hours or workstation platforms. Beckman Coulter estimates that this new turnkey solution could process circa 1,000 PCR samples per Biomek workstation installed during a standard 8-hour working day, using just a 0.5 full-time-equivalent in technician time for processing.
David Budd, CEO of genedrive plc, said: "We are very pleased to have the partnership of Beckman Coulter in accessing significant COVID testing opportunities throughout the United States and Europe, where the incidence of COVID continues to escalate and the need for high throughout testing solutions remains a priority. The combination of genedrive and Beckman Coulter products and expertise provides the Company with a new, innovative, and competitive solution, and a new sales channel for the American market, which we did not have previously.
"We are very pleased to now take our initial collaboration and development agreement to the commercial stage. Beckman Coulter is an important and significant company in these core geographies, well suited to promoting, selling, and supporting our products."
Great RNS - ready to take off.
This will be going back up to 85p again soon.
Drop to give you a chance to top up.
Booom Booom ....
Well done again another fantastic day.
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter") for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive's high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory viral samples. The agreement is the result of the collaboration agreement announced in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation in conjunction with its RNAdvance Viral XP extraction kit.
The Genedrive® 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument. The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent based test formulation. Full automation of the overall PCR workflow can allow laboratories to run large numbers of tests over extended working hours or workstation platforms. Beckman Coulter estimates that this new turnkey solution could process circa 1,000 PCR samples per Biomek workstation installed during a standard 8-hour working day, using just a 0.5 full-time-equivalent in technician time for processing.
David Budd, CEO of genedrive plc, said: "We are very pleased to have the partnership of Beckman Coulter in accessing significant COVID testing opportunities throughout the United States and Europe, where the incidence of COVID continues to escalate and the need for high throughout testing solutions remains a priority. The combination of genedrive and Beckman Coulter products and expertise provides the Company with a new, innovative, and competitive solution, and a new sales channel for the American market, which we did not have previously.
"We are very pleased to now take our initial collaboration and development agreement to the commercial stage. Beckman Coulter is an important and significant company in these core geographies, well suited to promoting, selling, and supporting our products."
This will be going to £5+ top up quickly at the bargain price.
Get ready for a Large order from the Government
https://bidstats.uk/tenders/2020/W53/741867528
I'm loading up at the bargain price. I have been given a second chance.
Thank you :-)
@T0n1c - thanks
So in summary.
No new news. Only regurgitated known news.
The fundamentals are the same. As confirmed by Omega|:
https://twitter.com/OmegaDiagnostic/status/1354503879732424708
The ONLY thing that has changed is that Abingdon "expects that any future orders will be received via an application by the Company to future DHSC tender notices" instead of under the initial framework agreement.
Last I researched, the RTC was still setup by the UK GOV, the ABC-19 was funded by the UK GOV. The ABC-19 test is still the gold standard AB LFT. In a 'competitive' tender I'm sure it will fair well.
https://twitter.com/Shredz90/status/1354495395670470656 - Thanks Shredz
Abingdon have confirmed they are still producing the ABC-19 tests, in readiness for orders.
A nice summary of probable ODX production numbers too:
https://twitter.com/MerchantBanke18/status/1354520054210162690 - Thanks MerchantBanker
In fact one other thing that may have also changed is that news of MHRA approval for home use has been granted. One for further digging.